The Michael J. Fox Foundation for Parkinson's Research has announced a commitment of up to $5.75 million as part of its 2010 Critical Challenges in Parkinson's Disease program.
This year, two of the challenges aim to streamline field-wide efforts focused on alpha-synuclein and LRRK2, two leading genetic targets for PD drug development. The third is designed to drive scientific collaborations that can accelerate progress by taking advantage of the unique repository of well-characterized biological samples collected through the brain and body donation program at the Arizona Parkinson's Disease Consortium.
Accepted projects will work to advance one or more of MJFF's key research priorities in PD drug development: defining Parkinson's disease and its progression, altering the course of the disease, reducing symptoms and complications of treatment to increase quality of life, and developing pre-clinical and clinical research tools to broadly accelerate Parkinson's research. Including the Critical Challenges commitment, MJFF expects this year to invest about $25 million in driving research focused on these priorities.
For details on each of the 2010 Critical Challenges, visit the MJFF Web site.